摘要
目的观察参芪注射液联合半剂量紫杉醇治疗晚期胃癌的近期疗效。方法采用参芪注射液联合半剂量紫杉醇治疗25例晚期胃癌,每疗程第1天紫杉醇45 mg/m^2持续静脉滴注3 h;参芪注射液250 ml/d,静脉滴注第1～14 d,间歇1周;每3周为1疗程,共3个疗程。观察疗效和患者血清白细胞介素-2水平变化。结果完全缓解(CR)1例,部分缓解(PR)13例,稳定11例,总有效率56.0%;主要毒性反应为白细胞减少21例(84.0%),脱发19例(76.0%),肌肉关节痛17例(68.0%),无治疗相关性死亡;治疗后患者血清白介素-2明显升高(P<0.01)。结论参芪注射液联合半剂量紫杉醇治疗晚期胃癌,近期疗效明显,未增加毒副反应,且可显著改善患者细胞免疫功能。
Objective To observer the recent therapeutic efficacy of ShenQi injection combined with half-dose paclitaxel （PTX） in the patients with advanced gastr/c cancer. Methods Twenty -five patients with advanced gastric cancer received half-dose PTX （ 45 mg/m2 , iv infusion,on day 1 ,every three weeks for one cycle） and ShenQi injection（250 ml/d,iv infusion, fi-om day 1 to day 14, every cycle）. All patients were evaluated after three cycles. Results Of the 25 patients, the response rate was 56. 0% （ 14/25 ）. The severe side-effects had not be observed. The level of cytokine interleukin-2 after treatment was （97. 87 ± 21.31 ） ng/L which significantly higher than that before treatment （ P 〈 0. 01 ）. Conclusions Shen Qi injection combined with half-dose PTX is effective, safe, and this therapy can improve cyto-immune function on patients with advanced gastric cancer.
出处
《中国厂矿医学》
2008年第4期395-396,共2页
Chinese Medicine of Factory and Mine
